iShares Gold Trust vs Roivant Sciences Ltd. Common Shares — how do they compare? iShares Gold Trust trades at $78.79 (market cap $61.51B), while Roivant Sciences Ltd. Common Shares trades at $35.12 (market cap $24.72B). The key difference: iShares Gold Trust is far larger — about 2.5× Roivant Sciences Ltd. Common Shares's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 49 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| IAU | ROIV | |
|---|---|---|
Market Cap | $61.51B | $24.72B |
Volume | 3,206,729 | 6,279,442 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $41.81 |
52-Week Low | $74.21 | $16.04 |
Typical Hold Time | 49 Days | 0 Days |
Enterprise Value | — | $20.99B |
Signals from Pluang's Aura AI — not financial advice
IAU is trading at $78.60, up 2.0% over the past 24 hours, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock faces resistance near $78-$79, with support at $76-$77. Recent news highlights sensitivity to interest rate expectations and Treasury yields, with gold's performance influencing sentiment. Financial ratios are currently unavailable for analysis.
The outlook remains cautious due to bearish technicals and macroeconomic pressures from rising yields. Investment opportunities may arise if the stock holds key support levels amid potential Fed policy shifts, but risks include further downside if rate-hike fears persist or economic data weakens gold's appeal.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →